Login to Your Account



Biogen Idec Quarter Solid As Tysabri Gathers Steam

By Randall Osborne


Wednesday, February 9, 2005
As some adopt a wait-and-see attitude to the company's new multiple sclerosis drug Tysabri (natalizumab, formerly Antegren), Biogen Idec Inc. reported satisfying fourth-quarter 2004 earnings and offered guidance for the coming year near the top end of consensus estimates. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription